To include your compound in the COVID-19 Resource Center, submit it here.

Halozyme starts Phase Ib/II of PEGPH20 plus Tecentriq

In October, Halozyme Therapeutics Inc. (NASDAQ:HALO) began the Phase Ib/II HALO-110-101 trial to evaluate PEGPH20 in combination with standard

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE